{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:35:51Z","timestamp":1773873351760,"version":"3.50.1"},"reference-count":95,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2021,4,3]]},"DOI":"10.1080\/14740338.2021.1887135","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T21:26:54Z","timestamp":1613251614000},"page":"397-409","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Risks and benefits of reducing the number of drugs to treat HIV-1 infection"],"prefix":"10.1080","volume":"20","author":[{"given":"Julen","family":"Cadi\u00f1anos","sequence":"first","affiliation":[{"name":"HIV Unit, Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Montejano","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"de Miguel Buckley","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Marcelo","sequence":"additional","affiliation":[{"name":"Internal Medicine Service, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose R.","family":"Arribas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Despacho 3.3. Hospital La Paz. IdiPAZ, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"cit0001","unstructured":"European AIDS clinical society guidelines[Internet]. [cited 2020 Oct 12]. Available from: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8431"},{"key":"cit0003","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents \u2013 a Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/clinicalinfo.hiv.gov\/es\/guidelines."},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1310\/hct1303-119"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2011.0275"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002311"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1577821"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1179\/1528433614Z.0000000015"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232473"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3666-8"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.716-723.2002"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-020-00266-3"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-014-0216-x"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30248-X"},{"key":"cit0015","first-page":"530","volume":"71","author":"Pozniak A","year":"2016","journal-title":"JAIDS"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12664"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)00024-2"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002699"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2808-8"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz056"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1605902"},{"key":"cit0024","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/hiv.12749","volume":"20","author":"Vallejo A","year":"2019","journal-title":"HIV Med"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002601"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002652"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-018-0701-x"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz511"},{"key":"cit0029","first-page":"e112","volume":"79","author":"Gianella S","year":"2018","journal-title":"JAIDS"},{"key":"cit0030","unstructured":"Rol\u00f3n MJ. Dual therapy with Lopinavir\/Ritonavir (LPV\/r) and Lamivudine (3TC) is non-inferior to standard triple drug therapy in na\u00efve HIV-1 infected subjects: 96-week results of the GARDEL Study. Exhibited at the 15th European AIDS Conference. 21-24 October 2015, Barcelona (Spain). Abstract PS10\/4."},{"key":"cit0031","first-page":"Abstract 489","author":"Figueroa MI","year":"2018","journal-title":"Exhibited at"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001058"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61170-3"},{"key":"cit0034","unstructured":"Cahn P, Sierra J, Arribas JR, et al. Durable efficacy of Dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection - 3 year results from the GEMINI studies. Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract P018."},{"key":"cit0035","unstructured":"Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir + rilpivirine for HIV treatment: FLAIR week 96 results. Exhibited at the Conference on Retroviruses and Opportunistic Infections. March 8-11 2020, Boston, Massachusetts (United States). Abstract 482."},{"key":"cit0036","author":"D\u2019Amico R","journal-title":"Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract O414."},{"key":"cit0037","unstructured":"Molina J-M, Yazdanpanah Y, Afani Saud A, et al. Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks. Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract O415."},{"key":"cit0038","unstructured":"Randomized, double-blind, efficacy, and safety study of doravirine\/islatravir (DOR\/ISL) in treatment-na\u00efve participants with human immunodeficiency virus type 1 (HIV-1) infection (MK-8591A-020) [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04233879."},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw379"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky123"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00096-1"},{"key":"cit0042","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","volume":"65","author":"Pulido F","year":"2017","journal-title":"Clin Infect Dis"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa018"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2020.1734752"},{"key":"cit0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciw207","volume":"63","author":"Pett SL","year":"2016","journal-title":"Clin Infect Dis"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187393"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2011.0336"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073639"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa356"},{"key":"cit0050","first-page":". Abstract O441","author":"van Wyk J","year":"2020","journal-title":"Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October"},{"key":"cit0051","unstructured":"Regimen switch to dolutegravir\/lamivudine fixed dose combination from current antiretroviral regimen in HIV-1 infected and virologically suppressed adults (SALSA) [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04021290."},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002449"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"cit0054","author":"Swindells S","journal-title":"Exhibited at the HIV Drug Therapy Glasgow Congress. 5-8 October 2020, Glasgow (United Kingdom). Abstract P006."},{"key":"cit0055","unstructured":"Overton ET, Richmond GJ, Rizzardini G. et al. Cabotegravir + Rilpivirine every 2 months is noninferior to monthly: ATLAS-2M STUDY. Exhibited at the Conference on Retroviruses and Opportunistic Infections. March 8-11 2020, Boston, Massachusetts (United States). Abstract 34."},{"key":"cit0056","unstructured":"Safety and efficacy of a switch to doravirine\/islatravir in participants with HIV-1 (MK-8591A-017) [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04223778."},{"key":"cit0057","unstructured":"Switch to doravirine\/islatravir (DOR\/ISL) in human immunodeficiency virus 1 (HIV-1) participants treated with bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) (MK-8591A-018) [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04223791."},{"key":"cit0058","unstructured":"Doravirine\/Islatravir (DOR\/ISL) in heavily treatment-experienced (HTE) participants for human immunodeficiency virus type 1 (HIV-1) Infection (MK-8591A-019) [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04233216."},{"key":"cit0059","unstructured":"Dose ranging, switch study of islatravir (ISL) and MK-8507 once-weekly in virologically-suppressed adults with human immunodeficiency virus type 1 (HIV-1) [MK-8591-013] [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564547."},{"key":"cit0060","unstructured":"WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/www.who.int\/publications\/guidelines\/hiv_aids\/en\/."},{"key":"cit0061","author":"Dovato","journal-title":"Eur Med Agency [Internet]."},{"key":"cit0062","author":"DOVATO","journal-title":"US Food Drug Adm [Internet]. [cited 2020 Oct 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211994Orig1s000Lbl.pdf"},{"key":"cit0063","author":"Rolle C","year":"2020","journal-title":"Exhibited at the HIV Drug Therapy Glasgow Congress"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz482"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2018.50.3.252"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017717018"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky299"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky125"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx068"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky212"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203452"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001557"},{"key":"cit0073","first-page":"Abstract OAXLB0","author":"Zash R","year":"2020","journal-title":"Exhibited at the International AIDS Conference"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2019.1628460"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105893"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ981"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz190"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002302"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2018.11.005"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1131"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002285"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2019.0147"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.09.002"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz009"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01247-1"},{"key":"cit0086","first-page":"336","volume":"26","author":"Ciccullo A","year":"2018","journal-title":"Infez Med"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw147"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002495"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2019.0253"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy113"},{"key":"cit0091","author":"Reynes J","year":"2020","journal-title":"Exhibited at the International AIDS Conference"},{"key":"cit0092","author":"de Miguel R","journal-title":"Exhibited at the Conference on Retroviruses and Opportunistic Infections. March 8-11 2018, Boston, Massachusetts (United States). Abstract 485.\u00a0"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001191"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104635"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101412"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2021.1887135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T05:03:02Z","timestamp":1697864582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2021.1887135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,3]]}},"alternative-id":["10.1080\/14740338.2021.1887135"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2021.1887135","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}